We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Dare Bioscience Inc (DARE) USD0.0001

Sell:$1.69 Buy:$1.76 Change: $0.1 (5.56%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: $0.1 (5.56%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: $0.1 (5.56%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health. Its portfolio of differentiated therapies expands treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Its product pipeline includes three product candidates in advanced stages of clinical development, three in Phase I clinical development and three in pre-clinical stage development. The product candidates in its pipeline include DARE-BV1, Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-FRT1, DARE-VVA1, DARE-LARC1, ORB-204 and ORB-214, and DARE-RH1. DARE-BV1 is focused on the treatment for bacterial vaginosis. Ovaprene is designed to provide multiple weeks of contraceptive protection and Sildenafil Cream, 3.6% is for the treatment of female sexual arousal disorders are under advanced stages of clinical development.

Contact details

3655 Nobel Dr Ste 260
United States
+1 (858) 9267655

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$137.88 million
Shares in issue:
76.60 million
United States
US dollar

Key personnel

  • Sabrina Johnson
    President, Chief Executive Officer, Secretary, Director
  • Lisa Walters-Hoffert
    Chief Financial Officer
  • John Fair
    Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.